bluebird bio Joins the Russell 2000® Index

  bluebird bio Joins the Russell 2000® Index

Business Wire

CAMBRIDGE, Mass. -- October 1, 2013

bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to
developing potentially transformative gene therapies for severe genetic and
orphan diseases, today announced that the company has been added to the
Russell 2000^®, Russell 3000^® and Russell Global^® Indexes as part of Russell
Investments’ third quarter IPO additions that took place after the market
closed on September 30, 2013.

The Russell 2000® Index measures the performance of the small-cap segment of
the U.S. equity universe. The Russell 2000^® is a subset of the Russell 3000^®
Index representing approximately 10% of the total market capitalization of
that index. It includes approximately 2000 of the smallest securities based on
a combination of their market cap and current index membership.

Russell Investments determines membership for its equity indexes primarily by
objective, market-capitalization rankings and style attributes. Approximately
$3.9 trillion in assets are currently benchmarked to the Russell Indexes

About bluebird bio, Inc.

bluebird bio is a clinical-stage company committed to developing potentially
transformative gene therapies for severe genetic and orphan diseases. bluebird
bio has two clinical-stage programs in development. The most advanced product
candidate, Lenti-D, recently initiated a phase 2/3 study for the treatment of
childhood cerebral adrenoleukodystrophy (CCALD), a rare, hereditary
neurological disorder affecting young boys. The next most advanced product
candidate, LentiGlobin, is currently in a phase 1/2 study in France for the
treatment of beta-thalassemia major and severe sickle cell disease. A second
phase 1/2 study with LentiGlobin in the United States has been initiated for
the treatment of beta-thalassemia major.

bluebird bio also has an early-stage chimeric antigen receptor-modified T cell
(CAR-T) program for oncology in partnership with Celgene Corporation.

bluebird bio has operations in Cambridge, Massachusetts and Paris, France. For
more information, please visit

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements
regarding the advancement of our clinical trials. Any forward-looking
statements in this press release are based on management's current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited to, the
risk of cessation or delay of any of the ongoing or planned clinical trials
and/or our development of our product candidates, the risk that the results of
previously conducted studies involving similar product candidates will not be
repeated or observed in ongoing or future studies involving current product
candidates, the risk that our collaboration with Celgene will not continue or
will not be successful, and the risk that any one or more of our product
candidates will not be successfully developed and commercialized. For a
discussion of other risks and uncertainties, and other important factors, any
of which could cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled "Risk Factors" in our
quarterly report on Form 10-Q, as well as discussions of potential risks,
uncertainties, and other important factors in our subsequent filings with the
Securities and Exchange Commission. All information in this press release is
as of the date of the release, and bluebird bio undertakes no duty to update
this information unless required by law.


Investor Relations:
bluebird bio, Inc
Richard E. T. Smith, Ph.D., 617-588-3321
Media Contact:
Pure Communications, Inc.
Dan Budwick, 973-271-6085
Press spacebar to pause and continue. Press esc to stop.